IL-6 Antibody [Unconjugated]

Recombinant Mouse IL‑6 (Catalog # 406-ML) stimulates proliferation in the T1165.85.2.1 mouse plasmacytoma cell line in a dose-dependent manner (orange line). Proliferation elicited by Recombinant Mouse IL‑6 (0.25 ng/mL) is neutralized (green line) by increasing concentrations of Goat Anti-Mouse IL‑6 Polyclonal Antibody (Catalog # AB-406-NA). The ND50 is typically0.05-0.15 µg/mL.

• Reactivity: Mu
• Applications: WB, B/N
• Clonality: Polyclonal
• Host: Goat
• Conjugate: Unconjugated
• Concentration: LYOPH

IL-6 Antibody [Unconjugated] Summary

• Immunogen: E. coli-derived recombinant mouse IL-6
  Phe25-Thr211
  Accession # P08505
• Specificity: Detects mouse IL-6 in direct ELISAs and Western blots. In direct ELISAs, approximately 30% cross-reactivity with recombinant rat IL‑6 is observed and less than 5% cross-reactivity with recombinant human IL‑6, recombinant feline IL‑6, recombinant bovine IL‑6, and recombinant porcine IL‑6 is observed.
• Source: N/A
• Isotype: IgG
• Clonality: Polyclonal
• Host: Goat
• Gene: IL6
• Purity Statement: Protein A or G purified
• Endotoxin Note: <0.10 EU per 1 μg of the antibody by the LAL method.

Applications/Dilutions

• Dilutions:
  • Neutralization 0.05-0.15 ug/mL
  • Western Blot 1 ug/mL

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.
• Preservative: No Preservative
• Concentration: LYOPH
• Reconstitution Instructions: Reconstitute at 1 mg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for IL-6 Antibody [Unconjugated]

• B-cell differentiation factor
• B-cell stimulatory factor 2
• BSF2
• BSF-2
• CDF
• CTL differentiation factor
• HSF
• hybridoma growth factor
• IFNB2
• IFN-beta-2
• IL6
• IL-6
• Interferon beta-2
• interleukin 6 (interferon, beta 2)
• interleukin BSF-2
• interleukin-6
• MGI-2A

Background

Interleukin-6 (IL-6) is a pleiotropic, alpha -helical, phosphorylated and variably glycosylated cytokine that plays important roles in the acute phase reaction, inflammation, hematopoiesis, bone metabolism, and cancer progression. Mature mouse IL-6 is 187 amino acids (aa) in length that is typically expressed as a 22-28 kDA molecular weight protein. Mouse IL-6 shares 39% and 85% aa sequence identity with human and rat IL-6, respectively. Alternative splicing generates several isoforms with internal deletions, some of which exhibit antagonistic properties. IL-6 induces signaling through a cell surface heterodimeric receptor complex composed of a ligand binding subunit (IL-6 R alpha) and a signal transducing subunit (gp130). IL-6 binds to IL-6 R alpha, triggering IL-6 R alpha association with gp130 and gp130 dimerization. gp130 is also a component of the receptors for CLC, CNTF, CT-1, IL-11, IL-27, LIF, and OSM. Soluble forms of IL-6 R alpha are generated by both alternative splicing and proteolytic cleavage. In a mechanism known as trans-signaling, complexes of soluble IL-6 and IL-6 R alpha elicit responses from gp130-expressing cells that lack cell surface IL-6 R alpha. Trans-signaling enables a wider range of cell types to respond to IL-6, as the expression of gp130 is ubiquitous, while that of IL-6 R alpha is predominantly restricted to hepatocytes, monocytes, and resting lymphocytes. Soluble splice forms of gp130 block trans-signaling from IL-6/IL-6 R alpha but not from other cytokines that use gp130 as a co-receptor. IL-6, along with TNF-alpha and IL-1, function to drive the acute inflammatory response and the transition from acute inflammation to either acquired immunity or chronic inflammatory disease. When dysregulated, it contributes to chronic inflammation in obesity, insulin resistance, inflammatory bowel disease, arthritis, sepsis, and atherosclerosis. IL-6 can also function as an anti-inflammatory molecule, as in skeletal muscle where it is secreted in response to exercise. In addition, it enhances hematopoietic stem cell proliferation and the differentiation of Th17 cells, memory B cells, and plasma cells.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for IL-6 Antibody (AB-406-NA)(9)

Publications using AB-406-NA

• Yanushko, D;German Falcon, B;El Bizri, R;Pervizou, D;Dolgos, R;Keime, C;Ye, T;Thibault-Carpentier, C;Le Magnen, C;Henri, S;Laverny, G;Metzger, D; p53-loss induced prostatic epithelial cell plasticity and invasion is driven by a crosstalk with the tumor microenvironment Cell death & disease 2025-01-26 [PMID: 39865080] (Neutralization, Mouse)
• Absalon D. Gutierrez, Zhanguo Gao, Vala Hamidi, Liang Zhu, Karla Bermudez Saint Andre, Kayla Riggs et al. Anti-diabetic effects of GLP1 analogs are mediated by thermogenic interleukin-6 signaling in adipocytes Cell Reports Medicine 2022-11-15 [PMID: 36384099]
• X Liu, E Zu, X Chang, X Ma, Z Wang, X Song, X Li, Q Yu, KI Kamei, T Hayashi, K Mizuno, S Hattori, H Fujisaki, T Ikejima, DO Wang Bi-phasic effect of gelatin in myogenesis and skeletal muscle regeneration Disease Models & Mechanisms, 2021-12-24;14(12):. 2021-12-24 [PMID: 34821368] (Neutralization, Mouse)
• JS Yi, SK Perla, LE Enyenihi, AM Bennett Tyrosyl phosphorylation of PZR promotes hypertrophic cardiomyopathy in PTPN11-associated Noonan syndrome with multiple lentigines JCI Insight, 2020-08-06;0(0):. 2020-08-06 [PMID: 32584792] (Neutralization, Mouse)
• S Mahmoudi, E Mancini, L Xu, A Moore, F Jahanbani, K Hebestreit, R Srinivasan, X Li, K Devarajan, L Prélot, CE Ang, Y Shibuya, BA Benayoun, ALS Chang, M Wernig, J Wysocka, MT Longaker, MP Snyder, A Brunet Heterogeneity in old fibroblasts is linked to variability in reprogramming and wound healing Nature, 2019-10-23;574(7779):553-558. 2019-10-23 [PMID: 31645721] (Cell Culture, Mouse)
• Laura N. Castellani, Willem T. Peppler, Paula M. Miotto, Natasha Bush, David C. Wright Exercise Protects Against Olanzapine-Induced Hyperglycemia in Male C57BL/6J Mice Scientific Reports 2018-01-15 [PMID: 29335597] (Neutralization, Mouse)
• Parker S. Woods, Mia F. Tazi, Nicholas M. Chesarino, Amal O. Amer, Ian C. Davis TGF-beta -induced IL-6 prevents development of acute lung injury in influenza A virus-infected F508del CFTR-heterozygous mice American Journal of Physiology-Lung Cellular and Molecular Physiology 2015-06-01 [PMID: 25840995]
• Julie Norseen, Tetsuya Hosooka, Ann Hammarstedt, Mark M. Yore, Shashi Kant, Pratik Aryal et al. Retinol-Binding Protein 4 Inhibits Insulin Signaling in Adipocytes by Inducing Proinflammatory Cytokines in Macrophages through a c-Jun N-Terminal Kinase- and Toll-Like Receptor 4-Dependent and Retinol-Independent Mechanism Molecular and Cellular Biology 2012-05-01 [PMID: 22431523] (Neutralization, Mouse)
• Kielar ML, John R, Bennett M Maladaptive role of IL-6 in ischemic acute renal failure. J. Am. Soc. Nephrol., 2005-09-28;16(11):3315-25. 2005-09-28 [PMID: 16192425] (Neutralization, Mouse)

FAQs for IL-6 Antibody (AB-406-NA). (Showing 1 - 1 of 1 FAQs).

1. I was wondering if you know of any blocking antibodies against IL-6 or VEGF-C that can be used in cell culture to quench these cytokines?
   • We have no antibodies that are currently known to show blocking antibodies to VEGF-C. Please see this link to our IL-6 antibodies with blocking/neutralizing activity can be found at this link.

Bioinformatics

• Gene Symbol: IL6
• Uniprot:
  • P08505()